Alimera Sciences, Inc. (NASDAQ:ALIM – Get Rating) saw a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 34,500 shares, an increase of 16.9% from the March 31st total of 29,500 shares. Based on an average daily volume of 42,300 shares, the short-interest ratio is currently 0.8 days. Approximately 0.7% of the company’s stock are sold short.
Several research firms have recently issued reports on ALIM. Alliance Global Partners reduced their target price on Alimera Sciences from $14.50 to $11.00 in a report on Friday, February 25th. HC Wainwright decreased their target price on Alimera Sciences from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, February 25th. Zacks Investment Research upgraded Alimera Sciences from a “strong sell” rating to a “hold” rating in a research note on Wednesday, April 27th. Finally, StockNews.com initiated coverage on shares of Alimera Sciences in a research report on Wednesday, April 27th. They set a “hold” rating for the company.
In related news, major shareholder Stanley Morgan sold 250,000 shares of the business’s stock in a transaction dated Tuesday, February 8th. The shares were sold at an average price of $4.55, for a total transaction of $1,137,500.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 13.50% of the stock is owned by company insiders.
Alimera Sciences stock opened at $5.40 on Wednesday. The business’s 50 day simple moving average is $5.50 and its 200 day simple moving average is $5.09. Alimera Sciences has a 12 month low of $3.94 and a 12 month high of $10.53.
Alimera Sciences (NASDAQ:ALIM – Get Rating) last issued its earnings results on Thursday, February 24th. The biopharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.38) by ($0.21). The business had revenue of $13.96 million during the quarter, compared to analysts’ expectations of $14.00 million. During the same quarter in the previous year, the firm posted ($0.18) EPS. On average, analysts predict that Alimera Sciences will post -1.89 earnings per share for the current year.
Alimera Sciences Company Profile (Get Rating)
Alimera Sciences, Inc, a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.
- Get a free copy of the StockNews.com research report on Alimera Sciences (ALIM)
- 3 Earnings Plays With Big Move Potential
- There Are Weeds In The Garden At Scotts Miracle-Gro
- It’s Time For FuboTV to Stand Out in the Sea of Streaming
- 3M Stock is Worth a Look Because of the Company it Keeps
- Landstar Systems Stock Can Bottom Down Here
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.